HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

iopromide (Ultravist)

structure given in first source

Also Known As:

Ultravist; Berlex brand of iopromide; Clarograf; Juste brand of iopromide; N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(2-methoxyacetamido)-N-methylisophthalamide; Schering brand of iopromide; Ultravist 300; iopromid; lopromid

Networked: 115 relevant articles (5 outcomes, 12 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58
- Carboxylic Acids: 83
  - Carbocyclic Acids
    - Benzoic Acids: 18
      - Benzoic Acid: 304
        Benzoates: 268
        Iodobenzoates
        Triiodobenzoic Acids: 2
        Iohexol: 464
        iopromide: 115

Experts

1.	Jost, Gregor: 7 articles (12/2014 - 04/2011)
2.	Pietsch, Hubertus: 7 articles (12/2014 - 04/2011)
3.	Mahnken, Andreas H: 3 articles (04/2012 - 04/2011)
4.	Krause, Werner: 3 articles (09/2011 - 05/2002)
5.	Lenhard, Diana C: 2 articles (12/2014 - 12/2011)
6.	Lengsfeld, Philipp: 2 articles (05/2012 - 12/2011)
7.	Kocabay, Gonenc: 2 articles (01/2012 - 01/2012)
8.	Wintersperger, Bernd J: 2 articles (01/2012 - 10/2007)
9.	Karabay, Can Yucel: 2 articles (01/2012 - 01/2012)
10.	Nikolaou, Konstantin: 2 articles (01/2012 - 10/2007)

Related Diseases

1.	Renal Insufficiency (Renal Failure) 01/01/1989 - "This open study showed that after i.v. injection of a bolus of iopromide 370, a new nonionic contrast medium, there was no untoward effect on renal function in patients with renal insufficiency. " 08/01/2001 - "These findings indicate that the determination of plasma clearance of iohexol/iopromide is a simple, rapid, and accurate method that can indeed be used for estimating GFR in ICU patients with normal renal function or even different degrees of renal insufficiency." 07/15/2011 - "Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography." 01/01/1998 - "The administration of the nonionic dimeric contrast medium iodixanol, or of the nonionic monomer iopromide, entailed a low nephrotoxic potential in patients with mild to moderate renal insufficiency undergoing excretory urography." 09/01/1998 - "This double blind, comparative, randomized, parallel trial compared the efficacy of iodixanol (non-ionic dimer) and iopromide (non-ionic monomer) in 100 patients with mild to moderate renal insufficiency (serum creatinine of 135 to 265 mumol l-1) who underwent i.v. urography. "
2.	Neoplasms (Cancer) 11/01/2014 - "Greater delivery of iopromide was shown to improve the precision of the measurement of tumor pHe, but the agent did not influence the tumor pHe. " 11/01/2014 - "The ratio of the two CEST effects was used to measure pH. Routes of administration of iopromide were evaluated to ensure sufficient delivery of the agent to the tumor. " 10/01/2013 - "Dynamic contrast-enhanced CT detects early treatment effects on tumor microvasculature after a single dose of regorafenib, independently of the used CA. Gadomer showed a later optimal imaging window than iopromide did. " 05/01/2002 - "To investigate the efficacy of the new liver-specific x-ray contrast agent, Dy-EOB-DTPA, in rabbits with VX2 liver tumors by spiral computed tomography (CT) in comparison to iopromide. " 09/01/2011 - "The aim of this study was to evaluate the computed tomography (CT)-imaging potential of iopromide-carrying liposomes (SPC/CH/SPG, 6:3:1) of approximately 200 nm in diameter in healthy rabbits and in rabbits with implanted liver tumors in an intraindividual comparison with iopromide. "
3.	Pain (Aches) 05/01/1994 - "On a scale of 0 (none) to 3 (severe) for heat and pain, respectively, the mean scores were 1.08 and 0.43 for iopromide in comparison with 1.15 and 0.35 for the comparator media. " 05/01/1994 - "Excellent tolerance was noted, with no patients reporting localized pain; there were low rates of mild to moderate warmth on injection (8.5% for iopromide versus 9.5% for comparators; P > .10). " 03/01/1994 - "Iopromide produced this sensitization at doses that did not elicit evident pain reactions per se. " 07/01/1997 - "Injection-associated pain in femoral arteriography: a European multicenter study comparing safety, tolerability, and efficacy of iodixanol and iopromide." 06/01/2012 - "Sixty seconds after injection, associated pain and heat sensation were less frequent in iodixanol in comparison with iopromide (P = 0.03). "
4.	Hypersensitivity (Allergy) 09/01/2005 - "The incidence of allergic reactions was similar if ioxaglate was used alone or in combination with iopromide (p=0.478). " 09/01/2005 - "In the "planned" group, 7 of 165 patients (4.2%) receiving ioxaglate had an allergic reaction as opposed 0.0% (0 of 124 patients) in the iopromide group (p=0.021). " 09/01/2005 - "With respect to the "follow on" group, allergic reactions occurred in 9 of 150 patients (6.0%) who received the combination of ioxaglate and iopromide versus 1 of 93 (1.1%) who only received iopromide (p=0.094). " 03/01/1995 - "Iopromide caused no appreciable hemodynamic alterations associated with the changes in atrial natriuretic peptide and antidiuretic hormone and no evidence of allergy-mediated reactions in all volunteers." 03/01/1995 - "Iopromide did not induce substantial changes in the other vasoactive peptides or in allergy-mediated substances after the contrast medium was injected. "
5.	Myocardial Infarction 01/01/1989 - "In spite of a bias--5 patients with iopromide 370 had myocardial infarction, versus one with ioxaglate 320--there were fewer adverse effects with iopromide 370. " 01/01/2012 - "In conclusion, in a population of unselected patients with ST-segment elevation acute myocardial infarction who underwent primary percutaneous coronary intervention, iopromide was not inferior to iodixanol in the occurrence of CI-AKI; no significant differences were found in terms of tissue-level reperfusion and major adverse cardiac events between the 2 contrast agents." 01/01/2012 - "Herein, we described a case of acute anterior myocardial infarction induced by the contrast agent iopromide (Ultravist). " 01/01/2012 - "The Contrast Media and Nephrotoxicity Following Coronary Revascularization by Angioplasty for Acute Myocardial Infarction (CONTRAST-AMI) trial is a prospective, randomized, single-blind, parallel-group, noninferiority study aiming to evaluate the effects of the low-osmolar contrast medium iopromide compared to the iso-osmolar agent iodixanol on CI-AKI and tissue-level perfusion in patients with ST-segment elevation acute myocardial infarction. "

Related Drugs and Biologics

1.	iodixanol (Visipaque)
2.	iopromide (Ultravist)
3.	Contrast Media
4.	Creatinine
5.	Iohexol (Omnipaque)
6.	dysprosium ethoxybenzyl DTPA
7.	Iodine
8.	Ioxaglic Acid (Ioxaglate Meglumine)
9.	iotrolan (Isovist)
10.	Sodium

Related Therapies and Procedures

1.	Angioplasty (Angioplasty, Transluminal)
2.	Catheters
3.	Intravenous Injections
4.	Transplants (Transplant)
5.	Homologous Transplantation (Allograft)